COMMUNICATION:
Redox Regulation of the DNA Binding Activity in Transcription Factor PEBP2
THE ROLES OF TWO CONSERVED CYSTEINE RESIDUES*

(Received for publication, March 19, 1997, and in revised form, March 31, 1997)

Yoshiko Akamatsu Dagger §, Tetsuya Ohno §, Kiichi Hirota , Hiroshi Kagoshima par , Junji Yodoi and Katsuya Shigesada **

From the Laboratory of Biochemistry, Department of Genetics and Molecular Biology and  Laboratory of Infection and Prevention, Department of Biological Responses, Institute for Virus Research, Kyoto University, Kyoto 606-01,-Japan

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENT
REFERENCES


ABSTRACT

Transcription factor PEBP2/CBF consists of a DNA binding subunit, alpha , and a regulatory subunit, beta . The alpha  subunit has an evolutionarily conserved 128-amino acid region termed "Runt domain" that is responsible for both DNA binding and heterodimerization with the beta  subunit. The Runt domain in all mammalian submembers of the alpha  subunit contains two conserved cysteine residues, and its DNA binding activity undergoes redox regulation. To investigate the mechanism of this redox regulation, we performed site-directed mutagenesis of the two conserved cysteines in the Runt domain of the mouse PEBP2alpha A homolog. Substitution of Cys-115 to serine resulted in a partially impaired DNA binding, which remained highly sensitive to a thiol-oxidizing reagent, diamide. Conversely, the corresponding substitution of Cys-124 caused an increased DNA binding concomitant with an increased resistance to diamide. In contrast, substitution of either cysteine to aspartate was destructive to DNA binding to marked extents. These results have revealed that both Cys-115 and Cys-124 are responsible for the redox regulation in their own ways with low and high oxidizabilities, respectively. We have also found that two cellular thiol-reactive proteins, thioredoxin and Ref-1, work effectively and synergistically for activation of the Runt domain. Interestingly, the beta  subunit further enhanced the activation by these proteins and reciprocally prevented the oxidative inactivation by diamide. These findings collectively suggest the possibility that the Runt domain's function in vivo could be dynamically regulated by the redox mechanism with Trx, Ref-1, and the beta  subunit as key modulators.


INTRODUCTION

Polyoma virus enhancer-binding protein 2 (PEBP2)1 (1), also called core binding factor (2), is a heterodimeric transcription factor composed of two different subunits, alpha  and beta . The alpha  subunit binds directly to a specific DNA sequence, RACCRCA, while the beta  subunit does not by itself contact with DNA but facilitates the DNA binding activity of the alpha  subunit through allosteric interactions (1, 2). The alpha  subunit shares a 128-amino acid region of high homology with the Drosophila segmentation gene runt (3) and the human AML1 gene (4). The conserved region, termed "Runt domain," is responsible for both DNA binding and heterodimerization with the beta  subunit (5, 6). After the identification of the first member of the alpha  subunit, PEBP2alpha A (1), two additional members of the Runt family have subsequently been isolated in mice and humans: PEBP2alpha B (mouse homolog of AML1) (7), and PEBP2alpha C (8) or AML2 (9).

In mammals, PEBP2 has been implicated in the transcriptional regulation of lymphoid cell-specific genes such as T-cell receptors, CD3, and myeloperoxidase, neutrophil elastase, granulocyte/macrophage colony-stimulating factor, macrophage colony-stimulating factor receptors, interleukin-3, and granzyme B (for review, see Ref. 10). Chromosomal translocations involving the human AML1 gene, such as t(8;21), t(3;21), and t(12;21), lead to various types of leukemia including acute myeloid leukemia, the blast crisis of chronic myeloid leukemia, and B-lineage acute lymphoblastic leukemia, respectively (for review, see Refs. 10 and 11). Moreover, an inversion in human chromosome 16 that gives rise to a fusion product, PEBP2beta -SMMHC (smooth muscle myosin heavy chain), was also found to cause a M4Eo subtype acute myeloid leukemia (12). Recent gene disruption studies in mice of AML1 (13) as well as PEBP2/CBFbeta (14) have confirmed that these genes are essential for definitive hematopoiesis.

Our previous functional characterization of PEBP2 (6) has revealed that the DNA binding activity of the Runt domain is subject to regulation by a reduction/oxidation-dependent mechanism (redox regulation). Since the finding of human thioredoxin/adult T-cell leukemia-derived factor (15), the importance of the thiol-mediated redox regulation has been well recognized in various biological responses (16, 17). Particularly notable are accumulating examples of redox-responsive transcription factors, such as the AP-1 family (18, 19), the Rel family (20-22), Myb (23), Ets-1 (24), and p53 (25). In these transcription factors, the reduced state of cysteine in the DNA-binding domain is essential for their DNA binding. Coincidentally, the Runt domain in all three mammalian submembers of the alpha  subunit contain two cysteine residues that are perfectly conserved among them (8). Our recent random mutagenesis study with the Runt domain of PEBP2alpha A (26) has suggested that one target for its redox regulation should be Cys-124, because substitution of this residue to serine resulted in an enhanced DNA binding concomitant with decreased redox-dependence. However, the possibility remains that the other cysteine residue, Cys-115, could also be redox-responsive. To further define the potential roles of the two conserved cysteine residues in the redox regulation of PEBP2, we performed their site-directed mutagenesis and examined the DNA binding ability of resulting mutants under various redox conditions in vitro.


EXPERIMENTAL PROCEDURES

Mutagenesis of the Runt Domain

Plasmid pQE-RD (6) encoding the Runt domain of PEBP2alpha A with an N-terminal hexahistidine tag (for its structure, see Fig. 1A) was used as a vector for construction and overexpression of Runt domain mutants. Each or both of Cys-115 and Cys-124 were mutagenized to serine or aspartate by polymerase chain reactions using Vent DNA polymerase (New England Biolabs) as described (27). The substitutions of the targeted residues were confirmed by sequencing.


Fig. 1. DNA binding activities of the wild type and its six cysteine substitution mutants. A, structures of PEBP2alpha A (top) and its hexahistidine-tagged Runt domain derivative (bottom). The two conserved cysteines (Cys-115 and Cys-124) and their flanking amino acids are shown in the box representing the Runt domain. The cysteines were changed to serine (S) or aspartate (D) as indicated. The arrows indicate the minimum regions responsible for DNA binding and heterodimerization with the beta  subunit. B, EMSA patterns of the Runt domain derivatives in the presence and absence of the beta  subunit as indicated. See "Results" for the notation of each construct. The bands were visualized and quantitated by a phosphorimager. Open, shaded, and solid arrows indicate the free DNA probe, the Runt domain-DNA complex, and the heterodimer-DNA complex, respectively. C, comparison of the DNA binding activities (% DNA bound) as measured above by EMSA. Open and solid bars stand for the activities obtained in the absence and presence of the beta  subunit, respectively. Striped bars indicate -fold stimulation by beta  subunit.
[View Larger Version of this Image (28K GIF file)]

Production and Purification of Proteins

His-tagged derivatives of the Runt domain and the beta  subunit were expressed in Escherichia coli and purified on a nickel-nitrilotriacetic acid resin (QIAGEN) as described (6). Trx was purchased from Ajinomoto. TrxR was purified as described (28). Ref-1 was purified as described (29).

Electrophoretic Mobility Shift Assay (EMSA)

A DNA probe containing the wild type PEBP2 binding site was prepared as described (6). The DNA binding reaction was routinely carried out for 10 min at 25 °C in 10 µl of the EMSA buffer containing 20 mM HEPES-KOH (pH 8.0), 4% (w/v) Ficoll 400, 2 mM EDTA, 100 mM KCl, 0.1 µg of poly(dI-dC), 6% glycerol, 0.2 mg/ml bovine serum albumin, 0.04% bromphenol blue, 10 fmol of 32P-labeled probe, 5 ng of purified His-tagged Runt domain, and the beta  subunit (50 ng) where indicated. In some experiments, the Runt domain was pretreated with redox reagents such as diamide, DTT, Trx, and Ref-1. The reaction mixture was loaded on a 10% nondenaturing polyacrylamide gel (acrylamide:bisacrylamide, 39:1) in 0.25 × Tris borate-EDTA buffer and electrophoresed at room temperature. Gels were dried and visualized by a phosphorimager (Fujifilm BAS 2000) or autoradiography with x-ray films.


RESULTS

The two conserved cysteine residues in the Runt domain of PEBP2alpha A to redox regulation were substituted to serine or aspartate, either separately or simultaneously (Fig. 1A). In the following, the resultant mutants are denoted by abbreviations in the form XY, in which the first and second letters represent amino acids in one-letter codes that replace Cys-115 and Cys-124, respectively. All the serine mutants showed readily detectable DNA binding, although those with Cys-115 substituted to serine (SC and SS) were severalfold less active than the wild type (CC) in the absence of the beta  subunit (Fig. 1B, left panel; see also Fig. 1C for quantitative comparison). In confirmation of our previous observation (26), mutant CS displayed stronger than normal DNA binding. On the other hand, the aspartate mutants invariably showed drastically impaired DNA binding, which was virtually undetectable in DC and DD, and barely recognizable in CD even after a prolonged exposure for autoradiography (Fig. 1B, right panel). When the beta  subunit was present, the wild type and all the mutants with any recognizable DNA binding activity gave supershifted DNA bands, whose intensities, except for CS, were prominently increased over those observed without the beta  subunit. This indicates that substitution of either cysteine residue to serine or aspartate is tolerable for the heterodimerization between the Runt domain and the beta  subunit as well as their allosteric regulatory interaction.

We then used the three serine mutants together with the wild type to evaluate the susceptibilities of the two cysteine residues to a thiol oxidizing reagent, diamide (Fig. 2A). Fig. 2B shows changes in the relative DNA binding activity of these constructs after their treatment with increasing concentrations of diamide relative to the respective mock-treated controls. In the absence of the beta  subunit (open circles), SC remained nearly as sensitive as the wild type to diamide, showing more than 75% inhibition at 1 mM. In contrast, CS was only weakly affected (25% inhibition) at 1 mM. However, the activity of this mutant was progressively and extensively decreased with further increments of diamide up to 100 mM. Thus we conclude that Cys-115 is also responsive to redox regulation, although being much less sensitive than Cys-124. When the beta  subunit was present, all variants having one or both cysteine residues showed decreased sensitivities to diamide. CC and SC remained 90% active at 1 mM, although they became drastically inactivated at higher concentrations; CS was only moderately inhibited even at 100 mM. Thus, the beta  subunit appeared to render both Cys-115 and Cys-124 tolerable to proportionately increased dosages of diamide by one order of magnitude or more. No such beta  subunit-dependent protection was observed with the cysteine-less mutant, SS, as expected.


Fig. 2. Effects of varying concentrations of diamide on the DNA binding activities of the wild type and serine-substituted Runt domain mutants. A, EMSA patterns of the respective proteins pretreated with indicated concentrations of diamide in the presence (right) and absence (left) of the beta  subunit at 25 °C for 10 min. Only the region covering shifted bands is shown. Notations and symbols are the same as in Fig. 1B. B, relative diamide sensitivities of the respective variants. The DNA binding activities of each construct measured above in the absence (open circles) and presence (solid circles) of the beta  subunit are replotted after normalization to the respective control values obtained with no added diamide. Crosses on dotted lines show -fold stimulation by the beta  subunit.
[View Larger Version of this Image (44K GIF file)]

In Fig. 2B are also indicated changes in the overall -fold stimulation of DNA binding by the beta  subunit with the diamide concentration for each Runt domain construct (crosses on dotted lines). Note first that SS showed moderate stimulation (severalfold), which is almost invariant with the diamide concentration and hence supposed to represent the redox-independent regulatory action of the beta subunit in augmenting the intrinsic affinity of the Runt domain for DNA as previously defined by Kagoshima et al. (6). By contrast, CC and SC exhibited much greater stimulation than SS, attaining a peak of 30-fold or more at 1 mM diamide. This enormous stimulation over that observed with SS is taken to reflect the above-noted anti-oxidation effect of the beta  subunit on Cys-124 as target. Although the -fold stimulation of CS was comparatively very low, it still showed a gradual rise with increasing concentrations of diamide, eventually surpassing that of SS at 100 mM. Evidently, therefore, Cys-115 is also subject to the protective action of the beta  subunit.

We further addressed the question of what cellular component(s) could serve for reductive activation of the Runt domain. Three known factors were tested as candidates: glutathione (GSH), Trx/ADF, and Ref-1. Trx/ADF is known to activate transcription factor NF-kappa B under the cooperation with TrxR and NADPH (15, 16, 28). Ref-1 (19) has been identified as a nuclear factor that stimulates the DNA binding activity of transcription factor AP-1. Ref-1, in turn, can be readily reduced by Trx (19). As shown in Fig. 3A, GSH was virtually inert in activating the Runt domain in the absence of the beta  subunit. When the beta  subunit was present, GSH showed moderate activation at low concentrations (1-10 µM: lanes 4 and 6), but it became inhibitory at 0.1 mM or above. In contrast, Trx consistently showed substantial activation at micromolar levels (Fig. 3B). Ref-1 was even more potent than Trx with still lesser concentrations (0.5-50 nM, Fig. 3C). Interestingly, the beta  subunit tended to stimulate the activation of the Runt domain by these proteins, particularly Ref-1 (Fig. 3C, even-numbered lanes). Possible mechanistic and regulatory implications of this effect will be given in "Discussion." Furthermore, Trx and Ref-1 were found to act synergistically with each other. When preoxidized CC was incubated with either of them alone supplemented with a minimum amount of DTT to quench the residual diamide, no or only marginal DNA binding was observed. In combination, however, they restored the DNA binding as effectively as 100 mM DTT (compare lanes 2 and 5). The effect of Trx was also improved considerably by its co-incubation with TrxR and NADPH (lane 6). In the presence of this coupled reducing system, the supplementary DTT could be omitted with only a moderate reduction in DNA binding (lane 7), which was again fully restored by the addition of Ref-1 (lane 8).


Fig. 3. Effects of various cellular thiol-reducing factors on the DNA binding activity of the Runt domain. In A-C, the wild type Runt domain was subjected to EMSA after co-incubation with increasing concentrations of indicated factors in the presence (even-numbered lanes) and absence (odd-numbered lanes) of the beta  subunit. A (GSH), lanes 1 and 2, none; lanes 3 and 4, 1 µM; lanes 5 and 6, 10 µM; lanes 7 and 8, 0.1 mM; lanes 9 and 10, 1 mM. B (Trx/ADF), lanes 1 and 2, none; lanes 3 and 4, 0.2 µM; lanes 5 and 6, 2 µM; lanes 7 and 8, 20 µM. C (Ref-1), lanes 1 and 2, none; lanes 3 and 4, 0.5 nM; lanes 5 and 6, 5 nM; lanes 7 and 8, 50 nM. D, CC was preoxidized with 1 mM diamide, treated with indicated thiol-reducing reagents either separately or simultaneously, and then subjected to EMSA: lane 1, 0.4 mM DTT; lane 2, 100 mM DTT; lane 3, 0.4 mM DTT and 20 µM Trx; lane 4, 0.4 mM DTT and 1 µM Ref-1; lane 5, 0.4 mM DTT, 20 µM Trx, and 1 µM Ref-1; lane 6, 0.4 mM DTT and Trx/TrxR system (20 µM Trx together with 5 × 104 units of TrxR and 1 mM NADPH); lane 7, Trx/TrxR system with no DTT; lane 8, Trx/TrxR system and 1 µM Ref-1. The EMSA pattern was visualized by autoradiography with x-ray films in A-C or by a phosphorimager in D. Shaded and solid arrows on the left indicate shifted bands due to the Runt domain alone and the Runt domain-beta subunit heterodimer, respectively.
[View Larger Version of this Image (56K GIF file)]


DISCUSSION

The present mutational study has demonstrated that both of the two cysteine residues within the Runt domain are responsible for redox regulation in their own ways, which are unique in comparison with known other redox-responsive transcription factors. Cys-124 apparently resembles the redox-responsive cysteine identified in Jun and Fos (18) in its high oxidizability due to flanking basic amino acids (Fig. 1A; see also Ref. 30) and augmented DNA binding by its substitution to serine. In Jun and Fos, conversion of cysteine to oxidation products of acidic nature is supposed to confer negative effects on DNA binding. A similar scenario would likely apply to Cys-124 in the Runt domain. Conversely, the lesser redox sensitivity of Cys-115 is likely attributable to the absence of any basic amino acid in its vicinity (Fig. 1A). Nevertheless, the reduced DNA binding activity caused by its substitution to serine as well as aspartate suggests that the free sulfhydryl group per se might be functionally essential. Similar mutational effects have previously been reported for NF-kappa B (21), Myb (23), and Ets-1 (24). Indeed, the x-ray structural analysis of NF-kappa B has demonstrated direct contacts of the free sulfhydryl group of cysteine with its target DNA (31). A priori, the two cysteines in the Runt domain might form a reversible disulfide bridge, as reported for p53 (25). However, their differential redox susceptibilities as observed rather favor the view that the two cysteines undergo redox reactions independently from each other. Such a two-pronged mechanism would enable more flexible regulation of DNA binding in response to diverse cellular redox signals than otherwise.

In extension of our previous observation (6), the results of this study also highlighted the potential significance of the beta  subunit as a modulator of redox sensitivity of the Runt domain, in addition to its role in allosterically enhancing the intrinsic DNA binding affinity of the Runt domain. The beta  subunit acted to protect both cysteines from oxidation by diamide. Puzzlingly, however, the beta  subunit did not hinder the access of the Runt domain by much larger molecules, Trx and Ref-1. How then was the beta  subunit able to block the action of diamide? We infer that the intrinsic oxidizability of these cysteine residues could be modulated by beta  subunit-induced alterations in the local environment around them in terms of their spatial alignment with neighboring charged amino acids or their involvement in intra- or inter-molecular hydrogen bonding, rather than a simple steric hindrance.

The finding that Trx and Ref-1 can efficiently activate the Runt domain in a manner synergistic with each other and enforceable by the beta  subunit raises the question of where and how these protein factors interact with each other within the cell. While the alpha subunit is a nuclear protein, the beta  subunit by itself is localized in the cytoplasm and transported to the nucleus through association with the alpha  subunit (32). Available evidence (6, 32) has suggested that the heteromeric interaction of the beta  subunit with the intact alpha  subunit is somewhat restricted both in vitro and in vivo by a putative intramolecular interference between the Runt domain and its flanking regions and that a specific mechanism would exist to promote this heterodimerization. Likewise, Ref-1 is a nuclear protein (19), whereas Trx is normally localized in the cytoplasm but is mobilized into the nucleus upon exposure of cells to various chemical and physical stimuli such as phorbol ester and ultraviolet (UV) irradiation (33). The expression of Trx also can be strongly induced by various oxidative stresses (34). In the light of these observations, it is tempting to speculate that the DNA binding activity of PEBP2 would be regulated by dynamic nuclear trafficking of the beta  subunit and Trx in response to oxidative stresses.

While this work was in progress, in vivo evidence underscoring the functional importance of cysteine residues in the Runt domain protein was provided by the report (35) that the transactivation and cell-transforming potentials of AML1/PEBP2alpha B were markedly weakened by substitution of serine for Cys-72 (corresponding to Cys-115 in PEBP2alpha A). To further delineate the dynamics and significance of redox regulation of PEBP2 to their full extents, it should be informative to extend such functional studies using a wider variety of mutants as constructed here in combination with various conditions affecting the cellular redox state.

Worth noting finally is the pattern of evolutionary conservation of cysteine in the Runt domain proteins. This protein family has been identified in a wide range of animal species from Caenorhabditis elegans (deduced from the C. elegans genomic data base)2 to mammals, and shown thus far to contain at least three subclasses in mammals (8-10) and two in Drosophila (Runt (3) and Lozenge (36)). As indicated in Fig. 4, all the members identified in species classified to deuterostomia including sea urchin (37), chicken (38), and mammals (8-10) share the two conserved cysteine residues at positions 115 and 124. On the other hand, those found in Drosophila and C. elegans, which belong to protostomia, have one or both of these cysteines altered to serine or tyrosine. Discernible also is an opposite change from cysteine to serine at position 157 in an apparent association with the advent of vertebrate. It thus seems that there were a number of possible ways in utilizing cysteine to control DNA binding by the Runt domain and nature had shifted its choices among them at major steps of evolutionary divergence in the animal kingdom. Further comparative studies of the Runt domain proteins are awaited to explore the potential evolutionary implications of its redox regulation in full scope.


Fig. 4. Phylogenetic comparison of the pattern of distribution of cysteine residues in the Runt domain. The amino acid sequences of Runt homologs identified to date in the indicated metazoan phyla were aligned together, and their amino acids are listed up for the positions within the Runt domain (numbered after PEBP2alpha A) at which cysteine was found in at least one of the homologs. See "Discussion" for the source of each sequence.
[View Larger Version of this Image (14K GIF file)]


FOOTNOTES

*   This work was supported in part by Research Grant RG-357/94 (to K. S.) from the Human Frontier Science Program Organization (Strasbourg) and by Research Project 08NP0601 (to J. Y.) under the "New Program System" of the Ministry of Education, Science, Culture and Sports of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Recipient of a research fellowship from the Japan Society for the Promotion of Science for Young Scientists. Present address: Dept. of Molecular Biology, Massachusetts General Hospital, 50 Blossom St., Boston, MA 02114.
§   The first two authors contributed to this work equally.
par    Present address: Biozentrum, der Universität Basel, Abteilung Zellbiologie, Klingelbergstr. 70, CH-4056 Basel, Switzerland.
**   To whom correspondence should be addressed. Tel.: 81-75-751-4019; Fax: 81-75-751-3992; E-mail: kshigesa{at}virus.kyoto-u.ac.jp.
1   The abbreviations used are: PEBP, polyoma virus enhancer-binding protein; Trx, thioredoxin; TrxR, thioredoxin reductase; EMSA, electrophoretic mobility shift assay; DTT, dithiothreitol.
2   H. Kagoshima and T. Bürglin, personal communication.

ACKNOWLEDGEMENT

We thank Dr. Thomas Bürglin (Basel University) for providing the deduced sequence of C. elegans Runt homolog.


REFERENCES

  1. Ogawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M., Shigesada, K., and Ito, Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6859-6863 [Abstract]
  2. Wang, S., Wang, Q., Crute, B. E., Melnikova, I. N., Keller, S. J., and Speck, N. A. (1993) Mol. Cell. Biol. 13, 3324-3339 [Abstract]
  3. Kania, M. A., Bonner, A. S., Duffy, J. B., and Gergen, J. P. (1990) Genes Dev. 4, 1701-1713 [Abstract]
  4. Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., and Ohki, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 10431-10434 [Abstract]
  5. Kagoshima, H., Shigesada, K., Satake, M., Ito, Y., Miyoshi, H., Ohki, M., Pepling, M., and Gergen, J. P. (1993) Trends Genet. 9, 338-341 [CrossRef][Medline] [Order article via Infotrieve]
  6. Kagoshima, H., Akamatsu, Y., Ito, Y., and Shigesada, K. (1996) J. Biol. Chem. 271, 33074-33082 [Abstract/Free Full Text]
  7. Bae, S. C., Yamaguchi-Iwai, Y., Ogawa, E., Maruyama, M., Inuzuka, M., Kagoshima, H., Shigesada, K., Satake, M., and Ito, Y. (1993) Oncogene 8, 809-814 [Medline] [Order article via Infotrieve]
  8. Bae, S. C., Takahashi, E., W., Zhang, Y., Ogawa, E., Shigesada, K., Namba, Y., Satake, M., and Ito, Y. (1995) Gene (Amst.) 159, 245-248 [CrossRef][Medline] [Order article via Infotrieve]
  9. Levanon, D., Negreanu, V., Bernstein, Y., Bar-Am, I., Avivi, L., and Groner, Y. (1994) Genomics 23, 425-432 [CrossRef][Medline] [Order article via Infotrieve]
  10. Speck, N. A., and Stacy, T. (1995) Crit. Rev. Eukaryot. Gene Exp. 5, 337-364 [Medline] [Order article via Infotrieve]
  11. Nucifora, G., and Rowley, J. D. (1995) Blood 86, 1-10 [Free Full Text]
  12. Liu, P., Tarle, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., and Collins, F. S. (1993) Science 261, 1041-1044 [Medline] [Order article via Infotrieve]
  13. Okuda, T., Deursen, J. V., Hiebert, S. W., Grosveld, G., and Downing, J. R. (1996) Cell 84, 321-330 [Medline] [Order article via Infotrieve]
  14. Wang, Q., Stacy, T., Miller, J. D., Lewis, A. F., Gu, T.-L., Huang, X., Bushweller, J. H., Bories, J.-C., Alt, F. W., Ryan, G., Liu, P. P., Wynshaw-Boris, A., Binder, M., Marin-Padilla, M., Sharpe, A. H., and Speck, N. A. (1996) Cell 87, 697-708 [Medline] [Order article via Infotrieve]
  15. Yodoi, J., and Uchiyama, T. (1992) Immunol. Today 13, 405-411 [CrossRef][Medline] [Order article via Infotrieve]
  16. Holmgren, A. (1989) J. Biol. Chem. 284, 13963-13966
  17. Schulze-Osthoff, K., Los, M., and Baeuerle, P. A. (1995) Biochem. Pharmacol. 50, 735-741 [CrossRef][Medline] [Order article via Infotrieve]
  18. Abate, C., Patel, L., Rausher, F. J., III, and Curran, T. (1990) Science 249, 1157-1161 [Medline] [Order article via Infotrieve]
  19. Xanthoudakis, S., Miao, G., Wang, F., Pan, Y.-C. E., and Curran, T. (1992) EMBO J. 11, 3323-3335 [Abstract]
  20. Toledano, M. B., and Leonard, W. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4328-4332 [Abstract]
  21. Matthews, J. R., Wakasugi, N., Virelizier, J.-L., Yodoi, J., and Hay, R. T. (1992) Nucleic Acids Res. 20, 3821-3830 [Abstract]
  22. Hayashi, T., Ueno, Y., and Okamoto, T. (1993) J. Biol. Chem. 268, 11380-11388 [Abstract/Free Full Text]
  23. Myrset, A. H., Bostad, A., Jamin, N., Lirsac, P., Toma, F., and Gabrielsen, O. S. (1993) EMBO J. 12, 4625-4633 [Abstract]
  24. Wasylyk, C., and Wasylyk, B. (1993) Nucleic Acids Res. 221, 523-529
  25. Hainaut, P., and Milner, J. (1993) Cancer Res. 53, 4469-4473 [Abstract]
  26. Akamatsu, Y., Tsukumo, S., Kagoshima, H., Tsurushita, N., and Shigesada, K. (1997) Gene (Amst.) 185, 111-117 [CrossRef][Medline] [Order article via Infotrieve]
  27. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59 [CrossRef][Medline] [Order article via Infotrieve]
  28. Kitaoka, Y., Sorachi, K., Nakamura, H., Masutani, H., Mitsui, A., Kobayashi, F., Mori, T., and Yodoi, J. (1994) Immunol. Lett. 41, 155-161 [CrossRef][Medline] [Order article via Infotrieve]
  29. Xanthoudakis, S., Miao, G., and Curran, T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 23-27 [Abstract]
  30. Snyder, G. H., Cennerazzo, M. J., Karalis, A. J., and Field, P. (1981) Biochemistry 20, 6509-6519 [Medline] [Order article via Infotrieve]
  31. Ghosh, G., Van Duyne, G., Ghosh, S., and Sigler, P. B. (1995) Nature 373, 303-310 [CrossRef][Medline] [Order article via Infotrieve]
  32. Lu, J., Maruyama, M., Satake, M., Bae, S. C., Ogawa, E., Kagoshima, H., Shigesada, K., and Ito, Y. (1995) Mol. Cell. Biol. 15, 1651-1661 [Abstract]
  33. Hirota, K., Matsui, M., Iwata, S., Nishiyama, A., Mori, K., and Yodoi, J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, in press
  34. Sachi, Y., Hirota, K., Masutani, H., Toda, K., Okamoto, T., Takigawa, M., and Yodoi, J. (1995) Immunol. Lett. 44, 189-193 [CrossRef][Medline] [Order article via Infotrieve]
  35. Kurokawa, M., Tanaka, T., Tanaka, K., Hirano, N., Ogawa, S., Mitani, K., Yazaki, Y., and Hirai, H. (1996) J. Biol. Chem. 271, 16870-16876 [Abstract/Free Full Text]
  36. Daga, A., Karlovich, C. A., Dumstrei, K., and Banerjee, U. (1996) Genes Dev. 10, 1194-1205 [Abstract]
  37. Coffman, J. A., Kirchhamer, C. V., Harrington, M. G., and Davidson, E. H. (1996) Dev. Biol. 174, 43-54 [CrossRef][Medline] [Order article via Infotrieve]
  38. Castagnola, P., Gennari, M., Gaggero, A., Rossi, F., Daga, A., Corsetti, M. T., Calabi, F., and Cancedda, R. (1996) Exp. Cell Res. 223, 215-226 [CrossRef][Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.